Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 16/20 | 0.44 |
| ▸ | PLG | P00747 | 14/20 | 0.44 |
| ▸ | ST14 | Q9Y5Y6 | 12/20 | 0.44 |
| ▸ | F10 | P00742 | 12/20 | 0.44 |
| ▸ | F2 | P00734 | 10/20 | 0.44 |
| ▸ | HPN | P05981 | 3/20 | 0.42 |
| ▸ | HGFAC | Q04756 | 3/20 | 0.42 |
| ▸ | PLAT | P00750 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13964837 | 1.00 | PLAU (0.44) | PLAUPLGST14F10F2 | |
| SCHEMBL13964843 | 0.86 | PLAU (0.44) | PLAUPLGST14F10F2 | |
| SCHEMBL3826016 | 0.86 | PLAU (0.44) | PLAUPLGST14F10F2 | |
| SCHEMBL13964831 | 0.84 | PLAU (0.43) | PLAUPLGST14F10F2 | |
| SCHEMBL3829057 | 0.69 | SMN1; SMN2 (0.46) | PLAUPLGST14F10F2 | |
| SCHEMBL2927549 | 0.66 | F10 (0.54) | PLAUPLGST14F10F2 | |
| SCHEMBL24183714 | 0.64 | FAAH (0.53) | — | |
| SCHEMBL20646451 | 0.63 | FCER2 (0.49) | — | |
| SCHEMBL22749410 | 0.63 | OPRD1 (0.52) | — | |
| SCHEMBL22749409 | 0.63 | OPRD1 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2099747-A1 | RADIOLABELLING VIA FLUORINATION OF AZIRIDINES | Bayer Schering Pharma Aktiengesellschaft (DE) | 2009-09-16 | — | — | EP | disclosed |
| US-20090022664-A1 | Radiolabelling via fluorination of aziridines | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2009-01-22 | — | — | US | disclosed |
| WO-2008083729-A1 | RADIOLABELLING VIA FLUORINATION OF AZIRIDINES | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2008-07-17 | — | — | WO | disclosed |
| EP-1944288-A1 | Radiolabelling via fluorination of aziridines | Bayer Schering Pharma Aktiengesellschaft (DE) | 2008-07-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090022664-A1 | Radiolabelling via fluorination of aziridines | TMEM14C, ARFGEF1, NPFFR1 | PLAU 4306/4885PLG 4510/4885ST14 2671/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.